{"id":389911,"date":"2021-12-29T00:00:00","date_gmt":"2021-12-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0004-2021-biopharma-gastric-cancer-china-in-depth-china-2021\/"},"modified":"2026-03-31T10:41:20","modified_gmt":"2026-03-31T10:41:20","slug":"concon0004-2021-biopharma-gastric-cancer-china-in-depth-china-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0004-2021-biopharma-gastric-cancer-china-in-depth-china-2021\/","title":{"rendered":"Gastric Cancer | China In-Depth | China | 2021"},"content":{"rendered":"<p>China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment\u2014trastuzumab (Roche\u2019s Herceptin, generics) as the first-line standard of care for HER2-positive gastric and gastroesophageal junction (GEJ) adenocarcinoma patients, apatinib (Jiangsu Hengrui Medicine\u2019s AiTan) and nivolumab (BMS\u2019s Opdivo) for third-line gastric and GEJ adenocarcinoma patients, pembrolizumab (Merck\u2019s Keytruda) for second-line esophageal squamous cell carcinoma patients, and camrelizumab (Jiangsu Hengrui Medicine\u2019s AiRuiKa) for first- and second-line advanced or metastatic esophageal squamous cell carcinoma. Several novel targeted therapies\u2014including VEGFR inhibitors (Eli Lilly\u2019s Cyramza and Chi-Med\u2019s Elunate), a claudin inhibitor (Ganymed\u2019s zolbetuximab), and several immune checkpoint inhibitors (Innovent Biologics\u2019 Tyvyt, BeiGene\u2019s Baizean, and CStone Pharmaceuticals\u2019 CS1001)\u2014are in preregistration or late-phase trials. The launch and uptake of these agents will lead to significant growth of the gastroesophageal cancer therapy market over the 2021-2031 period. However, the need for additional effective targeted therapies will remain high, representing a lucrative commercial opportunity for developers.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul>\n<li>How large is China\u2019s drug-treatable gastroesophageal cancer population, and how will drug-treatment rates change during the forecast period?<\/li>\n<li>Which are the most commercially relevant drugs in China\u2019s gastroesophageal cancer market, and why? What are interviewed experts\u2019 insights into current treatment options?<\/li>\n<li>What are the key market access considerations for therapies in the gastroesophageal cancer pipeline in China? What sales \/ uptake could they secure in gastroesophageal cancer? What are interviewed experts\u2019 opinions of key emerging therapies?<\/li>\n<li>What are the key drivers and constraints in China\u2019s gastroesophageal cancer therapy market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p>PRODUCT DESCRIPTION<\/p>\n<p>China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&#038;R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical\u00a0development, subpopulation targeting, physician messaging, and overall\u00a0long-term strategy in China.<\/p>\n","protected":false},"template":"","class_list":["post-389911","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-gastric-cancer","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389911\/revisions"}],"predecessor-version":[{"id":576291,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389911\/revisions\/576291"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}